WCM
ACOR

Wedge Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Wedge Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-304
Closed -$485K – 647
2019
Q1 		$485K Buy
+304
New +$548K 0.01% 457

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wedge Capital Management's ACOR Position: Q2 2019 in Review

Wedge Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 304 shares — an estimated $485K sold.

Wedge Capital Management first reported a position in ACOR in Q1 2019 and held it in 1 quarter. The position peaked at $485K in Q1 2019. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Wedge Capital Management reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wedge Capital Management sold 304 Acorda Therapeutics shares in Q2 2019, an estimated $485K.
  • Wedge Capital Management first reported a position in Acorda Therapeutics in Q1 2019 and held it in 1 quarter.
  • Wedge Capital Management's Acorda Therapeutics position peaked at $485K in Q1 2019.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Wedge Capital Management's 13F filing for Q2 2019, filed 1 Aug 2019.